We don't lead. We bridge.
Patient capital from Taiho Pharmaceutical's $400M corporate fund — for breakthrough therapeutics moving from preclinical to proof of concept.
A syndicate partner. Not a lead.
Top-tier institutional VCs lead the rounds. We bring what they can't. A global pharma cap-table signal. R&D infrastructure across three therapeutic areas. A commercial gateway to Asia. Patient capital, by design.
We syndicate alongside the institutional investors you already know — and we bring pharma to the cap table.
Capital is the table stakes. The rest is what we bring.
Patient capital
Backed by a $400M corporate fund and Taiho Pharmaceutical's balance sheet. We hold longer than a 7-year clock allows.
Pharma infrastructure
Direct access to Taiho's R&D, clinical, and commercialization teams across oncology, immunology, and urology.
Asian commercial gateway
A demonstrated path to Asian commercialization for Western biotech — through licensing, co-development, or build-to-buy.
Flexible deal structures
Syndicate equity, company creation, build-to-buy, option deals. Stage-aware, never stage-agnostic.
Receipts. Not pitches.
All case studies →Cullinan Pearl
EGFR Exon 20 inhibitorRe-acquired by Taiho Pharmaceutical, 2024 — proof of build-to-buy.SYNDICATE · Cullinan Oncology · Adams Street · Taiho VenturesArcus Biosciences
A2aR / A2bR antagonist · AB928Asian rights in-licensed by Taiho. Listed NASDAQ:RCUS.SYNDICATE · Foresite · GV · Novartis · Taiho VenturesOrna Therapeutics
Circular RNA platformSeries B, $221M. Platform validated by global pharma syndicate.SYNDICATE · MPM BioImpact · Novartis · Merck · Taiho VenturesHarpoon Therapeutics
TriTAC T-cell engagersAcquired by Merck, 2024. Strategic risk-sharing alongside lead VCs.SYNDICATE · ARCH · MPM · NEA · Taiho Ventures
Twenty-three companies. Three therapeutic areas. One thesis.
Strategic. Not stage-agnostic.
If you're building therapeutics in oncology, immunology, or urology — preclinical through proof of concept — we should talk.